About ARAV

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ARAV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.7 B 1.87292E+10 3,568 3568 0.0% 0 13 K 13374
IWC iShares Microcap ETF 916.2 M 9.16246E+08 1,452 1452 0.01% 0.0001 120 K 120401
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.0 B 2E+09 1,005 1005 0.0% 2.50828E-05 50 K 49644

Wait, Before You Leave...